Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia
A Randomized, Double-Blind, Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia
Sponsor: NeurogesX
Listed as NCT00068081, this PHASE3 trial focuses on Herpes Zoster and Neuralgia and remains completed. Sponsored by NeurogesX, it has been updated 6 times since 2026, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- NeurogesX
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Atlanta, United States, Boynton Beach, United States, Bradenton, United States, Brighton, United States, Dallas, United States, Duarte, United States, Fort Myers, United States, Marietta, United States, Mesa, United States, Naples, United States and 8 more location s